Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | XL092 |
Synonyms | |
Therapy Description |
XL092 is a receptor tyrosine kinase inhibitor that targets MET, AXL, VEGFR2, TYRO3, and MER, which potentially leads to decreased tumor cell proliferation and inhibition of tumor growth (PMID: 36399631). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
XL092 | XL-092|XL 092|Zanzalintinib | MET Inhibitor 59 VEGFR Inhibitor (Pan) 36 | XL092 is a receptor tyrosine kinase inhibitor that targets MET, AXL, VEGFR2, TYRO3, and MER, which potentially leads to decreased tumor cell proliferation and inhibition of tumor growth (PMID: 36399631). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06571734 | Phase II | XL092 | XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma | Recruiting | USA | 0 |
NCT06568562 | Phase II | XL092 | XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer (PRO-XL) | Not yet recruiting | USA | 0 |
NCT05176483 | Phase I | Nivolumab + NKTR-214 XL092 Nivolumab + NKTR-214 + XL092 Ipilimumab + Nivolumab + XL092 Nivolumab + XL092 Ipilimumab + Nivolumab | Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors (STELLAR-002) | Recruiting | USA | POL | NZL | ITA | ISR | GBR | FRA | ESP | DEU | CHE | BEL | AUT | AUS | 0 |
NCT03845166 | Phase I | XL092 | A Study of XL092 in Subjects With Solid Tumors | Active, not recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | CZE | BEL | AUS | 0 |